Targeting βII-Spectrin (SPTBN1) in a tissue-specific manner offers a promising avenue for managing obesity and its complications, including progression to liver diseases and HCC (Rao et al. 2021; Yang et al. 2024). Here, SPTBN1 is linked to obesity disorder.